Proteasome Inhibitors Fail to Show Measurable Bone and Quality-of-Life Benefits in Myeloma Patients

Multiple myeloma is a cancer of the plasma cells that burrows into bone marrow and wreaks havoc on the skeleton. In the vast majority of patients, the disease triggers osteolytic lesions—punched-out holes in the bone where malignant plasma cells have tipped the delicate balance between bone-building cells and bone-destroying cells firmly toward destruction. The result is often devastating: bone pain, fractures, spinal cord compression, and a cascade of complications that can be as disabling as the cancer itself. Now a new prospective study from an interdisciplinary team at the Medical Center–University of Freiburg, working with colleagues at the National and Kapodistrian University of Athens, offers a sobering reality check on one of the most widely used classes of myeloma drugs and its assumed benefits for bone health and quality of life.

The study, published in BMC Cancer, set out to answer a deceptively simple question: do patients actually feel better, and do their bones fare better, when they are being treated with proteasome inhibitors? These drugs—which include bortezomib, carfilzomib, and ixazomib—block the proteasome, a cellular waste-disposal complex that myeloma cells depend on to clear misfolded proteins. When the proteasome is inhibited, toxic protein accumulation builds up inside the malignant cells and triggers their death. This mechanism has transformed myeloma survival over the past two decades, and proteasome inhibitors are now embedded in nearly every modern treatment regimen, from newly diagnosed patients to those with relapsed and refractory disease.

But proteasome inhibitors may do more than kill myeloma cells. Laboratory studies have long suggested they carry bone-modulating effects that go beyond their anticancer activity, potentially suppressing the overactive osteoclasts that chew away at bone while influencing the osteoblasts that should rebuild it. If those biological effects were meaningful in real patients, you might expect to see the benefits show up in the clinic—in less bone pain, fewer osteolytic lesions, and better patient-reported quality of life. The Freiburg team wanted to know whether this theoretical promise survives contact with routine clinical practice, where treatment decisions are anything but random.

That caveat is crucial, and it shaped the study’s design. In routine care, physicians preferentially assign proteasome inhibitor-based therapy to patients with more active or more symptomatic disease. This means patients on these drugs are, by definition, likely sicker to begin with—a classic case of confounding by indication that would make naive comparisons deeply misleading. To address this, the researchers prospectively enrolled 209 patients with multiple myeloma during routine interdisciplinary follow-up, stratifying them by whether they were currently receiving proteasome inhibitor-based treatment or a non-PI-based regimen. Of the cohort, 78 patients, or 37 percent, were on proteasome inhibitor-based therapy at the time of assessment. Sixty-nine patients were reassessed after at least six months, allowing the team to track changes over time.

The investigators deployed multivariable regression and sensitivity analyses designed specifically to address baseline imbalances and the treatment selection problem. Patient-reported outcomes were captured using validated instruments measuring overall quality of life and health-related functional status, while skeletal symptoms were assessed through structured evaluation of bone pain and imaging-documented osteolytic lesions. This combination of subjective, patient-centered measures and objective skeletal endpoints is what makes the study unusual—it bridges hematology, orthopedics, and trauma surgery in a way that reflects how myeloma patients actually experience the disease.

The headline result is one of careful null findings. After adjustment, current proteasome inhibitor-based treatment status was not associated with meaningful differences in quality of life, with a standardized effect estimate of −0.08 and a 95 percent confidence interval spanning −0.45 to 0.29 and a p-value of 0.662. Health-related status told the same story, at −0.06 with a confidence interval of −0.42 to 0.30 and a p-value of 0.740. Bone pain showed no significant association either, with an odds ratio of 0.92 and a confidence interval of 0.48 to 1.74, and neither did the prevalence of osteolytic lesions, at an odds ratio of 1.26. During the six-month follow-up period, quality of life and health-related status remained comparable between the groups, suggesting no divergence in how patients felt over time depending on their current treatment class.

There was one signal worth watching, even if it fell short of statistical significance. Myeloma-related bone pain was numerically more frequent among patients currently receiving proteasome inhibitor-based treatment—46 percent versus 33 percent in the non-PI group. After multivariable adjustment, the association yielded an odds ratio of 1.80 with a confidence interval of 0.93 to 3.48 and a p-value of 0.081, hovering just above the conventional threshold for significance. The authors are careful here, and rightly so: this is precisely the pattern you would expect from confounding by indication, since clinicians reserve these potent drugs for patients with more active, more symptomatic disease. The excess pain likely reflects why those patients were on proteasome inhibitors in the first place, not a harmful effect of the drugs themselves.

What the study does not claim is nearly as important as what it does. The team explicitly states that these findings provide a real-world description of patient-reported and skeletal outcomes according to current treatment status, but they do not establish whether the biological effects of proteasome inhibitors on bone remodeling translate into clinically meaningful patient-reported or structural skeletal benefits. This is the persistent gap between bench and bedside that the study illuminates so clearly. Preclinical data on proteasome inhibition and osteoclast biology remain biologically plausible, yet the messy realities of clinical medicine—physician judgment, patient selection, concurrent antiresorptive therapy, and disease heterogeneity—obscure any signal that might exist. A randomized comparison, which would be ethically and practically difficult given the established efficacy of proteasome inhibitors against the cancer itself, would be needed to isolate the skeletal effects specifically.

For patients and clinicians, the practical message is one of reassurance with nuance. Being on a proteasome inhibitor was not associated with worse quality of life or health status in this cohort, which matters because these drugs carry well-known side effect profiles, including peripheral neuropathy that can compound a patient’s symptom burden. At the same time, patients on these drugs should not expect them to deliver measurable bone-protective benefits beyond their antimyeloma activity. Skeletal protection in multiple myeloma still rests on established pillars: bisphosphonates and other antiresorptive agents, orthopedic management of lytic lesions and fracture risk, and prompt control of the underlying disease. The study underscores that quality of life and bone pain in myeloma are shaped by many forces beyond a single drug class.

The research also highlights the value of prospective, interdisciplinary cohort designs in oncology. By following patients through routine hematology and orthopedic follow-up simultaneously, the Freiburg team captured a picture of myeloma care that is closer to everyday practice than most clinical trials can offer. As proteasome inhibitors become a permanent fixture of myeloma therapy, studies like this one serve as an essential reality check—reminding the field that biological promise, statistical adjustment, and the lived experience of patients with aching bones do not always align. The next challenge is to determine, with better-designed comparisons, whether the bone-modulating potential of these drugs can ever be converted into tangible relief for the patients who need it most.

Subject of Research: Patient-reported outcomes and skeletal symptoms in multiple myeloma patients receiving proteasome inhibitor-based versus non-PI-based therapy

Article Title: Patient-reported outcomes and skeletal symptoms in multiple myeloma stratified by proteasome inhibitor-based therapy: a prospective interdisciplinary cohort study

Article References: Patient-reported outcomes and skeletal symptoms in multiple myeloma stratified by proteasome inhibitor-based therapy: a prospective interdisciplinary cohort study. (n.d.). https://doi.org/10.1186/s12885-026-17177-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17177-7

Keywords: multiple myeloma, proteasome inhibitors, patient-reported outcomes, quality of life, bone pain, osteolytic lesions, bone remodeling, antiresorptive therapy, hematology-oncology, prospective cohort study, osteoimmunology, real-world evidence